Manipulating mitochondrial electron flow enhances tumor immunogenicity

Kailash Chandra Mangalhara(Salk Institute for Biological Studies), Siva Karthik Varanasi(Salk Institute for Biological Studies), Melissa Johnson(Salk Institute for Biological Studies), Mannix J. Burns(Salk Institute for Biological Studies), Gladys R. Rojas(Salk Institute for Biological Studies), Pau B. Esparza‐Moltó(Salk Institute for Biological Studies), Alva G. Sainz(Salk Institute for Biological Studies), Nimesha Tadepalle(Salk Institute for Biological Studies), Keene L. Abbott(Broad Institute), Gaurav Mendiratta(Salk Institute for Biological Studies), Dan Chen(Salk Institute for Biological Studies), Yagmur Farsakoglu(Salk Institute for Biological Studies), Tenzin Kunchok(Whitehead Institute for Biomedical Research), Filipe Araujo Hoffmann(Salk Institute for Biological Studies), Bianca Parisi(Salk Institute for Biological Studies), Mercedes Rincón(University of Colorado Anschutz Medical Campus), Matthew G. Vander Heiden(Broad Institute), Marcus Bosenberg(Yale University), Diana C. Hargreaves(Salk Institute for Biological Studies), Susan M. Kaech(Salk Institute for Biological Studies), Gerald S. Shadel(Salk Institute for Biological Studies)
Science
September 21, 2023
Cited by 112Open Access
Full Text

Abstract

Although tumor growth requires the mitochondrial electron transport chain (ETC), the relative contribution of complex I (CI) and complex II (CII), the gatekeepers for initiating electron flow, remains unclear. In this work, we report that the loss of CII, but not that of CI, reduces melanoma tumor growth by increasing antigen presentation and T cell-mediated killing. This is driven by succinate-mediated transcriptional and epigenetic activation of major histocompatibility complex-antigen processing and presentation (MHC-APP) genes independent of interferon signaling. Furthermore, knockout of methylation-controlled J protein (MCJ), to promote electron entry preferentially through CI, provides proof of concept of ETC rewiring to achieve antitumor responses without side effects associated with an overall reduction in mitochondrial respiration in noncancer cells. Our results may hold therapeutic potential for tumors that have reduced MHC-APP expression, a common mechanism of cancer immunoevasion.


Related Papers